References
Nakamoto Y, Kurihara K, Nishizawa M, Yamashita K, Nakatani K, Kondo T, et al. Clinical value of 11C-methionine PET/CT in patients with plasma cell malignancy: comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:708–715. doi:10.1007/s00259-012-2333-3.
Luckerath K, Lapa C, Albert C, Herrmann K, Jorg G, Samnick S, et al. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget. 2015;6:8418–8429. doi:10.18632/oncotarget.3053.
Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jorg G, et al. (11)C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6:254–261. doi:10.7150/thno.13921.
Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68. doi:10.1186/1477-7819-5-68.
Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477–487. doi:10.15252/emmm.201404698.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by the Wilhelm-Sander-Stiftung (grant no. 2013.906.1).
Rights and permissions
About this article
Cite this article
Lapa, C., Schirbel, A., Samnick, S. et al. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. Eur J Nucl Med Mol Imaging 44, 1097–1098 (2017). https://doi.org/10.1007/s00259-017-3656-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-017-3656-x